News Story: Full Text
Sponsored By
Cedars-Siani Medical Center Brain Tumor Program
Please Click On The Above Banner For More Details
Braintumor Website

 

Association between human cytomegalovirus infection and histone acetylation level in various histological types of glioma.

Al's Comment:

 This is a controversial topic in the brain tumor world. Studies have shown that most or all gbm samples contain this virus. However, other studies show that few or none have it.  That difference may be related to the ability of the lab to detect it. There needs to be a standardized way of detecting it so we can settle that once and for all. There has been a human study of an anti CMV  drug (Valcyte) that has shown very good results, but the study was questioned by others saying it wasn't designed properly.  My thoughts are we need more studies on anti-CMV therapies, but in the meantime it might be worth adding it to the planned treatment regimen.  It would be best to track patients who try this in our brain tumor virtual trial so we can quickly tell if there is any effect - good or bad.


Posted on: 01/05/2016

  Oncol Lett. 2015 Nov;10(5):2812-2820. Epub 2015 Aug 25.
Association between human cytomegalovirus infection and histone acetylation level in various histological types of glioma.
Huang R1, Qian D1, Hu M1, Zhang X1, Song J1, Li L1, Chen H1, Wang B1.
 
Author information:
1Department of Microbiology, Qingdao University Medical College, Qingdao, Shandong 266071, P.R. China.
 
Abstract
 
At present, glioma is the most common intracranial tumor and accounts for 40-60% of intracranial tumors. Glioma is highly anaplastic and demonstrates invasive growth. Although considerable progression has been achieved in the treatment of malignant glioma, the prognosis of this disease remains poor. Over the previous decade, several studies have confirmed that human cytomegalovirus (HCMV) enhances the growth or survival of tumors. This is likely to occur through mechanisms distinct from those of classic tumor viruses, which express transforming viral oncoproteins in the majority of tumor cells. The immediate-early 2 protein (IE86; 86 kDa) of HCMV is a key regulator for viral replication and host cell proliferation. The present study aimed to identify the association between the acetylation level and HCMV IE86 expression in various histological types of glioma. Tissue samples were obtained from 60 patients with glioma, consisting of 25 patients with glioblastoma multiforme (GBM), 16 patients with anaplastic glioma and 19 patients with low-grade glioma, in addition to 9 tissue samples obtained from the normal cortex, which were used as the control. The in situ protein expression of IE86, which is encoded by the IE2 gene, activating transcription factor 5 (ATF5), P300, acetyl-histone H3K9 and acetyl-histone H3K14 was detected by immunohistochemistry. The mRNA levels of ATF5, IE2 and P300 were measured by reverse transcription-quantitative polymerase chain reaction in GBM, anaplastic glioma, low-grade glioma and normal cortex tissue specimens. The protein levels of ATF5, IE86, P300, acetyl-histone H3K9 and acetyl-histone H3K14 were assessed by western blot analysis in high-grade glioma, low-grade glioma and normal cortex tissues. Analysis of the expression of the proteins revealed that the excessive expression of the HCMV IE86 protein is associated with the malignancy degree and acetylation level in glioma. IE86 expression is also associated with ATF5, which is an anti-apoptotic protein that is highly expressed in malignant glioma, but not in normal brain tissues. The expression level of IE86 may demonstrate considerable importance for the evaluation of the malignancy degree of human gliomas and extensive application in diagnostic and therapeutic medicine.
PMID: 26722247 [PubMed]

 


Click HERE to return to brain tumor news headlines


Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2018 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740